menu
    • menu
    [{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for SLV213

    cayman pipeline prospector

    Virtual Booth

    Contact Supplier

    Check COS database
    Check USDMF database

    Contact Us
    PharmaScopic.com

    Click to view the API/FDF
    Pricing Demo Dashboard
    Menu

    SLV213

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selva Announces Preclinical Data Confirming SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Varia...

                            Details : New preclinical data demonstrated, that dosing of SLV213 at picomolar concentrations delivered near-complete inhibition of infection by the Omicron variant of SARS-CoV-2 in a human lung epithelial cell line (A549_ACE2).

                            Product Name : SLV213

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selva to Present Preclinical Data at ASV 2021 on Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lung...

                            Details : SLV213 is a novel, orally available, small molecule antiviral investigational drug that inhibits human host cell cysteine proteases to block viral entry.

                            Product Name : SLV213

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 19, 2021

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for ...

                            Details : Company has received U.S. FDA clearance of an Investigational New Drug Application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Preclinical data show SLV213 is a potent inhibitor of SARS-CoV-2 inf...

                            Product Name : SLV213

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Selva Therapeutics

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $3.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Selva Therapeutics Announces $3 Million Series A Financing to Advance a Novel Broad Spectrum Antiviral for COV...

                            Details : The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.

                            Product Name : SLV213

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 21, 2020

                            Lead Product(s) : SLV213

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $3.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth